AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • AstraZeneca Plc (NASDAQ:AZN) has filed suit against former VP and head of investor relations Chris Sheldon as he prepares to start a new job at GSK plc (NYSE:GSK) in September, Bloomberg reported.
  • In a London court filing, AstraZeneca argued that Sheldon would be violating a non-compete agreement, which he was paid more than $774,000 in shares to sign in 2021, Bloomberg reported.
  • Sheldon worked at AstraZeneca for more than 18 years. He resigned earlier this month, effective immediately, according to Law360
  • According to the Bloomberg report, GSK poached Sheldon and another senior dealmaker to boost its cancer therapies and other drugs pipeline. 
  • Sheldon was tasked with identifying late-stage deal opportunities. 
  • AstraZeneca previously headed to court to protect its interests after a senior executive left for a close rival. In 2017 it sued former executive Luke Miels who also moved to GSK. 
  • AstraZeneca and GSK settled in court, with Miels taking a “gardening leave” until joining GSK in September 2017. 
  • However, according to The Times in London, Miels accused Soriot of threatening him over his visa during the resignation dispute.
  • Price Action: GSK shares are down 2.52% at $34.37, and AZN stock is up 0.90% at $67.34 on the last check Wednesday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechLarge CapNewsHealth CareLegalManagementGeneralBriefs